Hospital
Leesburg Regional Medical Center, INC.
Leesburg Regional Medical Center, INC. was paid $6.96M by Medicaid between Jan 2018 and Dec 2024, across 152 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoLEESBURG REGIONAL MEDICAL CENTER, INC.
LEESBURG, FL 34748
LEESBURG, FL 34748
33aNPI1154868693assigned 01/23/2017
33bProvider typePsychiatric Hospital Unit
28Total paid$6.96M
24GClaims267,267
24DCodes billed152
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Florida
Rank by total paid#9 of 15
Median peer was paid$7.13M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,047 | $451K | |
| 2019 | 64,007 | $1.26M | |
| 2020 | 44,009 | $1.07M | |
| 2021 | 51,952 | $1.42M | |
| 2022 | 52,600 | $1.53M | |
| 2023 | 22,153 | $827K | |
| 2024incomplete | 8,499 | $412K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 17,824 | 16,031 | $1.35M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 16,559 | 14,133 | $1.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.4% | 4,120 | 3,412 | $375K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 5.1% | 4,604 | 4,312 | $353K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.8% | 3,523 | 2,837 | $336K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.8% | 4,583 | 4,161 | $334K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.3% | 2,826 | 1,698 | $300K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.2% | 4,417 | 3,329 | $294K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.1% | 1,606 | 1,425 | $289K |
| 80053 | Comprehensive metabolic panel | 3.6% | 17,707 | 13,023 | $254K |
| 81001 | 3.3% | 10,133 | 8,653 | $233K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.5% | 1,659 | 1,434 | $174K |
140 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.5% | 1,009 | $174K |
| 36415 | Collection of venous blood by venipuncture | 2.3% | 6,544 | $163K |
| G0378 | Hospital observation service, per hour | 2.1% | 7,051 | $149K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1.2% | 1,855 | $81K |
| 87400 | 1.1% | 1,485 | $79K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,467 | $52K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,939 | $50K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,986 | $48K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 933 | $40K |
| 82962 | <1% | 5,497 | $34K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,502 | $30K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 671 | $27K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,368 | $26K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,698 | $26K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 240 | $25K |
| A9270 | Non-covered item or service | <1% | 3,893 | $24K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 617 | $23K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,832 | $21K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 241 | $21K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 282 | $21K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,297 | $19K |
| 86850 | <1% | 886 | $19K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,578 | $18K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 452 | $17K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,751 | $16K |
| 85610 | <1% | 7,644 | $16K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 267 | $15K |
| 86140 | <1% | 1,545 | $14K | |
| 84484 | <1% | 7,542 | $13K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 524 | $13K |
| 76818 | <1% | 413 | $12K | |
| 94761 | <1% | 2,580 | $11K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 337 | $11K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,241 | $10K |
| J3490 | Unclassified drugs | <1% | 1,660 | $9K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,109 | $8K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,027 | $8K |
| 85730 | <1% | 5,953 | $7K | |
| 96376 | <1% | 1,761 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,826 | $7K |
| 81025 | <1% | 2,827 | $7K | |
| 83880 | <1% | 2,658 | $6K | |
| 86900 | <1% | 1,300 | $6K | |
| 84703 | <1% | 1,833 | $6K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 132 | $6K |
| 83735 | <1% | 3,926 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,852 | $5K |
| 82550 | <1% | 442 | $4K | |
| 94664 | <1% | 733 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,493 | $4K |
| 73564 | <1% | 230 | $4K | |
| 83690 | <1% | 4,960 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,870 | $3K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 12 | $3K |
| 73630 | <1% | 217 | $3K | |
| 73610 | <1% | 224 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,075 | $3K |
| 86901 | <1% | 1,248 | $3K | |
| 84702 | <1% | 1,335 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 935 | $2K |
| 73030 | <1% | 144 | $2K | |
| 87186 | <1% | 1,338 | $2K | |
| 76801 | <1% | 404 | $2K | |
| 73110 | <1% | 89 | $2K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 79 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 804 | $2K |
| 12001 | <1% | 14 | $1K | |
| J2770 | Injection, quinupristin/dalfopristin, 500 mg (150/350) | <1% | 168 | $1K |
| 85027 | <1% | 482 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 320 | $1K |
| 74018 | <1% | 152 | $1K | |
| 87077 | <1% | 840 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 728 | $1K |
| 84100 | <1% | 1,071 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 40 | $1K |
| 73130 | <1% | 66 | $1K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 16 | $969.88 |
| 93017 | <1% | 28 | $968.91 | |
| 93971 | <1% | 40 | $932.52 | |
| 87807 | <1% | 510 | $929.10 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 77 | $687.91 |
| 87040 | <1% | 1,328 | $571.24 | |
| 85014 | <1% | 27 | $557.83 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 188 | $526.42 |
| 85018 | <1% | 100 | $421.74 | |
| 84145 | <1% | 510 | $338.00 | |
| 85379 | <1% | 322 | $323.99 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 580 | $320.70 |
| 87070 | <1% | 14 | $316.27 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 189 | $310.98 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 142 | $307.71 |
| 72100 | <1% | 28 | $289.46 | |
| 59025 | Fetal non-stress test | <1% | 21 | $243.95 |
| 80061 | Lipid panel | <1% | 224 | $195.32 |
| 74022 | <1% | 32 | $192.92 | |
| J2704 | Injection, propofol, 10 mg | <1% | 311 | $171.31 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 175 | $164.32 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 13 | $160.00 |
| 73502 | <1% | 16 | $156.74 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 45 | $145.12 |
| 83605 | <1% | 719 | $140.66 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 210 | $115.30 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 187 | $98.63 |
| 82248 | <1% | 570 | $84.94 | |
| 82247 | <1% | 56 | $77.50 | |
| 80143 | <1% | 161 | $61.50 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 68 | $34.73 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 17 | $29.02 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 621 | $27.86 |
| 84436 | <1% | 57 | $20.19 | |
| 90715 | <1% | 32 | $14.32 | |
| 87641 | <1% | 30 | $13.92 | |
| 87081 | <1% | 233 | $9.42 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 515 | $9.16 |
| 82077 | <1% | 393 | $7.79 | |
| 84132 | <1% | 19 | $1.48 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 591 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 264 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 266 | $0.00 |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 121 | $0.00 |
| 99406 | 0% | 45 | $0.00 | |
| 86141 | 0% | 116 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 122 | $0.00 |
| 84480 | 0% | 33 | $0.00 | |
| 94760 | 0% | 175 | $0.00 | |
| 82150 | 0% | 32 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 13 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 33 | $0.00 |
| C1769 | Guide wire | 0% | 17 | $0.00 |
| 85652 | 0% | 25 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 84 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 16 | $0.00 |
| 80179 | 0% | 159 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 18 | $0.00 |
| 96367 | 0% | 14 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 14 | $0.00 |
| 84550 | 0% | 12 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 137 | $0.00 |
| 87210 | 0% | 16 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARDEN, DIANE (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Pathology Services Alliance LLC | Leesburg, FL | $25K |
| Alliance Labs, LLC | Leesburg, FL | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.